AR013821A1 - Compuesto de xantina, procedimiento para su preparacion, medicamento y uso de los mismos para preparar un medicamento. - Google Patents
Compuesto de xantina, procedimiento para su preparacion, medicamento y uso de los mismos para preparar un medicamento.Info
- Publication number
- AR013821A1 AR013821A1 ARP970102447A ARP970102447A AR013821A1 AR 013821 A1 AR013821 A1 AR 013821A1 AR P970102447 A ARP970102447 A AR P970102447A AR P970102447 A ARP970102447 A AR P970102447A AR 013821 A1 AR013821 A1 AR 013821A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- representing
- branched
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de xantina, caracterizado porque comprende la formula I en forma pura segun los estereoisomeros o como mezclas de estereoisomeros,representando en ella 1) R2 y R3 un radical de alquinol de la formula Ia o Ib, R2 a) alquilo C1-5line al o ramificado, b)cicloalquilo C3-6 o c) cicloalquil-alquilo C4-8, R4 un átomo de hidrogeno o alquilo C1-3, R5, R6 y R7, independientemente unos de otros, a)un átomo de hidrogeno, b)alquilo C1-6, c)cicloalquilo C3-6, d) cicloalquil- alqui lo C4-8, e) ar-alquilo C1-2 o f) tri- alquil C1-4-sililo, o formando R5 y R6 en comun con el átomo de nitrogeno, alque están unidos, un anillo saturado de 4 hasta 7 miembros, el cual está sin sustituir o sustituído de una a cuatro vecescon alq uilo C1-4, o formando R5 yR6 en comun con el átomo de nitrogeno, al que están unidos, un anillo saturado de 4 a 7 miembros, en el que un grupo -CH2- del anillo está reemplazado por unradical tomado del grupo formado por O, S, SO, SO2 yNR13, R13 rep resenta un átomo de hidrogeno, alquil C1-3-carbonilo o alquilo C1-4, y el anillo está sinsustituir o sustituído de una a cuatro veces con alquilo C1-4, representando A alquileno C1-6 sin ramificar o ramificado, y representando Zel anion de uná cido inorgánico u orgánico, fisiologicamente compatible, o representando en ella 2) R1 o R3 un radical de alquinol de formula Ia o Ib y el otro radical R3o R1 a) un átomo de hidrogeno o b) R8, en que R8 significa alquilo C1-6lineal o ramificado, cicloalquilo C3-6 o cicloalquil-alquilo C4-8 y estando definidosR2, R4, R5, R6, R7, A y Z como en 1).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19622734A DE19622734A1 (de) | 1996-06-07 | 1996-06-07 | Xanthinverbindungen mit terminal aminierten Alkinol-Seitenketten |
| DE1996136882 DE19636882A1 (de) | 1996-09-11 | 1996-09-11 | Xanthinverbindungen mit terminal aminierten Alkinol-Seitenketten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR013821A1 true AR013821A1 (es) | 2001-01-31 |
Family
ID=26026371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970102447A AR013821A1 (es) | 1996-06-07 | 1997-06-05 | Compuesto de xantina, procedimiento para su preparacion, medicamento y uso de los mismos para preparar un medicamento. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US5965555A (es) |
| EP (1) | EP0811623B1 (es) |
| JP (1) | JP4263778B2 (es) |
| KR (1) | KR100531964B1 (es) |
| CN (1) | CN1064361C (es) |
| AR (1) | AR013821A1 (es) |
| AT (1) | ATE200288T1 (es) |
| AU (1) | AU712717B2 (es) |
| BR (1) | BR9703500B1 (es) |
| CA (1) | CA2207258C (es) |
| CZ (1) | CZ292509B6 (es) |
| DE (1) | DE59703271D1 (es) |
| DK (1) | DK0811623T3 (es) |
| ES (1) | ES2155640T3 (es) |
| GR (1) | GR3035711T3 (es) |
| HU (1) | HU224702B1 (es) |
| ID (1) | ID17468A (es) |
| IL (1) | IL120998A (es) |
| MX (1) | MX9704201A (es) |
| MY (1) | MY117764A (es) |
| NO (1) | NO307787B1 (es) |
| NZ (1) | NZ328018A (es) |
| PL (1) | PL186238B1 (es) |
| PT (1) | PT811623E (es) |
| RU (1) | RU2204561C2 (es) |
| TW (1) | TW384289B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2284708A (en) * | 1993-12-07 | 1995-06-14 | At & T Corp | Method for passivation of multi-quantum well infrared photodetectors (QWIPS) to reduce dark current and to improve dark current uniformity |
| KR100926247B1 (ko) * | 2001-02-24 | 2009-11-12 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법 |
| US6881738B2 (en) * | 2001-07-19 | 2005-04-19 | Medical College Of Georgia Research Institute | Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders |
| CN107674077A (zh) * | 2002-08-21 | 2018-02-09 | 勃林格殷格翰制药两合公司 | 8‑[3‑氨基‑哌啶‑1‑基]‑黄嘌呤化合物，其制备方法及作为药物制剂的用途 |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| NZ573360A (en) | 2006-05-04 | 2012-08-31 | Boehringer Ingelheim Int | Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP2190434B1 (en) * | 2007-08-17 | 2019-04-17 | Boehringer Ingelheim International GmbH | Purin derivatives for use in the treatment of fap-related diseases |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| JP5906086B2 (ja) * | 2008-08-15 | 2016-04-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｆａｂ関連疾患の治療に用いるためのプリン誘導体 |
| JP2012502081A (ja) | 2008-09-10 | 2012-01-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糖尿病及び関連症状の治療のための組み合わせ治療 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| TWI508965B (zh) | 2008-12-23 | 2015-11-21 | Boehringer Ingelheim Int | 有機化合物的鹽形式 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| JP2013512229A (ja) | 2009-11-27 | 2013-04-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 遺伝子型が同定された糖尿病患者のリナグリプチン等のｄｄｐ−ｉｖ阻害薬による治療 |
| NZ602921A (en) | 2010-05-05 | 2016-01-29 | Boehringer Ingelheim Int | Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor |
| MX2012014247A (es) | 2010-06-24 | 2013-01-18 | Boehringer Ingelheim Int | Terapia para la diabetes. |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| EP3468562A1 (en) | 2016-06-10 | 2019-04-17 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4007197A (en) * | 1975-06-10 | 1977-02-08 | The Dow Chemical Company | Process for preparing phosphorothioates and phenylphosphonothioates |
| DE3525801A1 (de) * | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
| EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
| GB8621870D0 (en) * | 1986-09-11 | 1986-10-15 | Beecham Group Plc | Active compounds |
| GB8826595D0 (en) * | 1988-11-14 | 1988-12-21 | Beecham Wuelfing Gmbh & Co Kg | Active compounds |
| US5473070A (en) * | 1992-11-16 | 1995-12-05 | Cell Therapeutics, Inc. | Substituted long chain alcohol xanthine compounds |
| IT1274241B (it) * | 1993-12-03 | 1997-07-15 | Smithkline Beecham Farma | Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono |
-
1997
- 1997-05-30 US US08/866,347 patent/US5965555A/en not_active Expired - Lifetime
- 1997-06-03 AT AT97108871T patent/ATE200288T1/de active
- 1997-06-03 PT PT97108871T patent/PT811623E/pt unknown
- 1997-06-03 DK DK97108871T patent/DK0811623T3/da active
- 1997-06-03 DE DE59703271T patent/DE59703271D1/de not_active Expired - Lifetime
- 1997-06-03 ES ES97108871T patent/ES2155640T3/es not_active Expired - Lifetime
- 1997-06-03 EP EP97108871A patent/EP0811623B1/de not_active Expired - Lifetime
- 1997-06-04 CN CN97112930A patent/CN1064361C/zh not_active Expired - Fee Related
- 1997-06-05 NZ NZ328018A patent/NZ328018A/en not_active IP Right Cessation
- 1997-06-05 AR ARP970102447A patent/AR013821A1/es active IP Right Grant
- 1997-06-05 AU AU24699/97A patent/AU712717B2/en not_active Ceased
- 1997-06-05 IL IL12099897A patent/IL120998A/xx not_active IP Right Cessation
- 1997-06-05 ID IDP971927A patent/ID17468A/id unknown
- 1997-06-05 CZ CZ19971742A patent/CZ292509B6/cs not_active IP Right Cessation
- 1997-06-06 RU RU97109533/04A patent/RU2204561C2/ru not_active IP Right Cessation
- 1997-06-06 JP JP16346697A patent/JP4263778B2/ja not_active Expired - Fee Related
- 1997-06-06 NO NO972581A patent/NO307787B1/no not_active IP Right Cessation
- 1997-06-06 CA CA002207258A patent/CA2207258C/en not_active Expired - Fee Related
- 1997-06-06 MX MX9704201A patent/MX9704201A/es not_active IP Right Cessation
- 1997-06-06 PL PL97320414A patent/PL186238B1/pl not_active IP Right Cessation
- 1997-06-06 MY MYPI97002536A patent/MY117764A/en unknown
- 1997-06-06 HU HU9701018A patent/HU224702B1/hu not_active IP Right Cessation
- 1997-06-07 KR KR1019970023483A patent/KR100531964B1/ko not_active IP Right Cessation
- 1997-06-09 BR BRPI9703500-9A patent/BR9703500B1/pt not_active IP Right Cessation
- 1997-06-24 TW TW086108159A patent/TW384289B/zh active
-
2001
- 2001-04-06 GR GR20010400561T patent/GR3035711T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR013821A1 (es) | Compuesto de xantina, procedimiento para su preparacion, medicamento y uso de los mismos para preparar un medicamento. | |
| AR031828A2 (es) | Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia | |
| ES2061462T3 (es) | Compuestos cefemo, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
| ECSP034563A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| KR870700620A (ko) | 신규 약리학적 화합물 | |
| ES2071621T3 (es) | Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen. | |
| AR014102A1 (es) | 4-haloalquil-3-heterociclilpiridinas y 4-haloalquil-5- heterociclilpirimidinas, procedimiento para su preparacion, productos que lascontienen, uso de las mismas para preparar un medicamento veterinario, procedimiento para proteger plantas cultivadas y su empleo para combatir | |
| AR078152A1 (es) | Compuestos heterociclicos, utiles para el tratamiento de hcv y composiciones farmaceuticas que los comprenden | |
| ES2058527T3 (es) | Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen. | |
| AR029210A1 (es) | DERIVADOS DE N-(5-SULFAMOIL-1,3-TIAZOL-2-IL) ACETAMIDA, PROCEDIMIENTO PARA SU PREPARACIoN, COMPUESTOS INTERMEDIARIOS, COMPOSICIoN FARMACÉUTICA, Y EL USO DE DICHOS DERIVADOS PARA LA PRODUCCIoN DE MEDICAMENTOS | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| ES2053508T3 (es) | Compuestos de acidos 3-pirrolidinil-tio-1-azabiciclo(3.2.0)hept-2-eno-2-carboxilicos. | |
| AR029463A1 (es) | Pirrolidinas disustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| AR038000A1 (es) | Compuesto derivado de tien[2,3-d]pirimidin-2,4(1h,3h)-diona, composicion farmaceutica, proceso para su preparacion y su uso en la fabricacion de un medicamento | |
| AR012436A1 (es) | Compuestos de 4-aminopirido[2,3-d]pirimidina 5,7-disustituidos, composicion farmaceutica que los comprende, el uso de los mismos para lamanufactura de medicamentos, un procedimiento para su preparacion. | |
| ES2032582T3 (es) | Procedimiento para preparar derivados de la oxima del 1,2,5,6,-tetrahidropiridin -3-carboxialdehido. | |
| ES2166098T3 (es) | Composiciones farmaceuticas que contienen acidos 4-oxo-butanoicos. | |
| ES2127263T3 (es) | Nuevos trien-derivados cromenicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
| SE8600658D0 (sv) | Novel composition of matter | |
| AR029618A1 (es) | Compuestos de amida , procedimientos para prepararlos, las composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos | |
| MX9300423A (es) | Derivados heterociclicos. | |
| UY27399A1 (es) | Proceso para la preparación de quinazolinas | |
| ES2145306T3 (es) | Nitro-benzamidas utiles como agentes anti-arritmicos. | |
| GB1319029A (en) | Organic nitro compounds | |
| PT95810A (pt) | Processo para a preparacao de composicoes farmaceuticas injectaveis contendo um alcaloide de bis-indol como ingrediente activo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |